Ofatumumab is a fully human anti- CD20 monoclonal antibody whose epitope is distinct from that of rituximab. [24] Ofatumumab binds to a distinct epitope on small and large extracellular loops of CD20. [25][26] The CD20 antigen is expressed on solely B cell lymphocytes. [24]

Jan 17, 2025 · Ofatumumab (brand name Kesimpta) is used in adults with specific types of relapsing forms of multiple sclerosis (MS) including: active secondary progressive disease (active SPMS). The most common ofatumumab side effects are: headache, tiredness. Ofatumumab can cause the following serious side effects. Infusion-related reactions.

A: Ofatumumab is a fully-humanized monoclonal anti-CD20 antibody constructed with recombinant DNA techniques and designed to selectively target CD20-expressing B-cells.

Mar 1, 2025 · Ofatumumab can temporarily lower the number of white blood cells in your blood, increasing the chance of getting a serious infection (eg, bacterial, fungal, viral). It can also lower the number of platelets, which are necessary for proper blood clotting.

Ofatumumab (Kesimpta ®) is a fully human anti-CD20 monoclonal antibody that can be self-administered by patients and is approved in several countries worldwide for the treatment of relapsing forms of multiple sclerosis (MS).

Ofatumumab injection is used to prevent episodes of symptoms and slow the worsening of disability in adults who have relapsing forms of multiple sclerosis (MS; a disease in which the nerves do not function properly and people may experience weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control ...

Ofatumumab, a novel humanized monoclonal anti-CD20 antibody, was recently approved by the FDA for the treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL).

Ofatumumab is an anti-CD20 antibody used for the treatment of chronic lymphocytic leukemia (CLL) in selected patients with certain treatment histories and responsiveness to anticancer medications. Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells.

Ofatumumab is an anti-CD20 IgG1κ human monoclonal antibody that is being considered by the US Food and Drug Administration and the European Medicines Agency for marketing approval as a treatment for chronic lymphocytic leukemia.

View ofatumumab information, including dose, uses, side-effects, pregnancy, breast feeding, contra-indications, monitoring requirements and directions for administration.